Introduction {#s1}
============

Invariant natural killer T (iNKT) cells are αβ T cells expressing semi-invariant T cell receptors (TCR) that respond to self-lipids or foreign-lipids presented by the MHC-I like antigen-presenting molecule CD1d ([@bib2]). They are numerically less abundant than conventional peptide recognizing CD4 and CD8 T cells but profoundly important, secreting a variety of cytokines early after stimulation or in the steady state to influence immune responses and tissue homeostasis ([@bib24]; [@bib27]; [@bib25]; [@bib16]). Previous work has demonstrated that despite being monospecific, iNKT cells display substantial functional heterogeneity ([@bib9]; [@bib12]; [@bib13]; [@bib20]; [@bib30]; [@bib37]; [@bib41]), being composed of three predominant effector subsets, NKT1, NKT2 and NKT17 according to the expression of key transcription factors and cytokine production ([@bib24]; [@bib18]). For instance, NKT1 cells are T-bet^+^ PLZF^low^ and produce IFN-γ; NKT17 cells are ROR-γt^+^ PLZF^int^ and produce IL-17; while NKT2 cells are PLZF^high^, and produce IL-4 ([@bib24]; [@bib18]). Through the selective activation and distinct localization of various iNKT effector subsets, iNKT cells can modulate immune responses and tissue homeostasis in different fashions ([@bib27]; [@bib25]; [@bib28]). iNKT cells are positively selected in the thymus, in response to agonist interactions with self-lipid/CD1d expressing double positive thymocytes (DP) in the thymic cortex ([@bib14]; [@bib17]; [@bib31]). At this point the cells express a high level of CD24, and are considered the most immature, or 'stage 0'. In contrast, matured functionally competent effector iNKT cells localize predominantly in the thymic medulla ([@bib25]), and thymic medullary epithelial cells impact their functional maturation ([@bib43]). Nonetheless, the developmental steps from stage 0 iNKT cells to mature iNKT effector subsets have remained unclear. Previous work used CD44 and NK1.1 to define 'stages' of iNKT development. However, more recent work showed that these markers are heterogeneously expressed on the mature cytokine producing iNKT effector subsets ([@bib9]; [@bib12]; [@bib13]; [@bib20]; [@bib30]; [@bib37]; [@bib41]). Therefore, the field lacks precise identification of an iNKT multipotent precursor cell. Previous work in our lab, using T-bet and IL-4 reporter mice, identified T-bet^+^ NKT1, ROR-γt^+^ NKT17, and IL-4^+^ PLZF^hi^ NKT2 cells as terminally differentiated ([@bib24]). However, IL-4^−^ PLZF^hi^ iNKT cells still retained precursor potential, and could convert to T-bet^+^ NKT1 cells in the thymus ([@bib24]). These results suggest there is heterogeneity within the PLZF^hi^ iNKT cell population, and led us to hypothesize that there exists a population of progenitor cells within the PLZF^hi^ iNKT cells. Indeed, transcriptional profiling by RNA-Seq indicated IL-4^−^ PLZF^hi^ iNKT cells had low similarity with the three effector subsets, including IL-4 producing PLZF^hi^ iNKT cells ([@bib26]). Single cell RNA-Seq analysis from another group also suggested there might be a progenitor population within the PLZF^hi^ iNKT cells ([@bib15]).

Here we identify a previously unknown sub-population of PLZF^hi^ CCR7^+^ iNKT cells as precursors for all three iNKT effector subsets. CCR7^+^ iNKT cells efficiently emigrate from the thymus in a *Klf2* dependent manner and then undergo further maturation on site. However, some iNKT cells maintain residency in the thymus where they undergo differentiation without circulating. The thymic and peripheral pools of iNKT effector subsets do not exchange and therefore depend on CCR7^+^ iNKT cells for their establishment. In addition to marking the precursor pool, CCR7 also directs iNKT progenitor cells to localize to the thymic medulla and is required for differentiation of iNKT effector subsets. We further establish that thymic iNKT cells influence T cell development and thymic tissue homeostasis.

Results {#s2}
=======

CCR7^+^ iNKT and MAIT cells are at an early stage of development and represent a precursor pool for effector subsets in the thymus {#s2-1}
----------------------------------------------------------------------------------------------------------------------------------

To identify iNKT cells at an early stage of development in the thymus, we used mice that express green fluorescent protein (GFP) under the control of the recombination-activating gene 2 (*Rag2*) promoter via a bacterial artificial chromosome transgene (*Rag2*^GFP^), in which GFP expression indicates the 'age' of cells ([@bib6]; [@bib29]). We found most thymic iNKT cells were *Rag2*^GFP^ negative, while a small proportion of iNKT cells express *Rag2*^GFP^ ([Figure 1A](#fig1){ref-type="fig"}). The iNKT cells with the highest GFP also express CD24 and high level of CD69, indicating they are stage 0 iNKT cells that are immediate after agonist selection ([Figure 1A](#fig1){ref-type="fig"}). Since we identified CCR7 as a potential progenitor specific gene ([@bib26]), and a small population of CCR7^+^ iNKT cells could be specifically detected ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}), we further examined CCR7 expression in iNKT cells in *Rag2*^GFP^ mice. CCR7^+^ iNKT cells expressed high to intermediate amounts of GFP, suggesting they are immature and recently derived from stage 0 iNKT cells ([Figure 1A](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). Whereas, the *Rag2*^GFP^ lowest cells (most mature) did not express CCR7 ([Figure 1A](#fig1){ref-type="fig"}). According to the conventional 'staging' system of iNKT cells in B6 mice, CCR7^+^ iNKT cells were predominantly NK1.1^--^ CD44^lo^ (stage 1) but also included some NK1.1^−^ CD44^+^ cells (stage 2) ([Figure 1B](#fig1){ref-type="fig"}), although most NK1.1^−^ CD44^+^ (stage 2) cells were not CCR7^+^ as this gate mostly included functionally mature NKT2 and NKT17 cells, and NKT1 cells were NK1.1^+^ CD44^+^ (stage 3) ([Figure 1B](#fig1){ref-type="fig"}). Furthermore, most CCR7^+^ iNKT cells did not express T-bet, ROR-γt, IL-4 (human CD2) ([Figure 1C](#fig1){ref-type="fig"}). Rather, CCR7^+^ iNKT cells expressed abundant PLZF and LEF1 ([Figure 1C](#fig1){ref-type="fig"}), which are both essential for iNKT cells development and proliferation ([@bib8]; [@bib34]; [@bib22]).

![Thymic CCR7^+^ iNKT and MAIT cells are at an early developmental stage and give rise to distinct effector subsets in the thymus.\
(**A**) Expression of *Rag2*^GFP^ and CCR7 in thymic iNKT cells (TCR-β^+^ CD1d-PBS57^+^) (left column), and of CD24 (middle column) and CD69 (right column) on cells with different levels of *Rag2*^GFP^. Data are representative of 3 independent experiments with 3--4 mice in each. (**B**) Expression of NK1.1 and CD44 in thymic CCR7^+^ iNKT (black dots), IL-4^+^ (human CD2^+^) NKT2 (red dots), ROR-γt^+^ NKT17 (blue dots), T-bet^+^ NKT1 (green dots) cells together with total thymic iNKT cells (grey dots). Numbers in quadrants indicate percent cells in each for CCR7^+^ iNKT (black dots), IL-4^+^ (human CD2^+^) NKT2 (red dots), ROR-γt^+^ NKT17 (blue dots) and T-bet^+^ NKT1 (green dots) cells. Data are representative of 4 independent experiments with 2--3 mice in each. (**C**) Expression of T-bet, ROR-γt, huCD2, PLZF, LEF1, Egr2 and CD4 with CCR7 in thymic iNKT cells (TCR-β^+^ CD1d-PBS57^+^ CD24^--^). Data are representative of 3 independent experiments with 2--3 mice in each. Numbers in quadrants indicate percent cells in each (throughout). (**D**) Frequency of Ki67^+^ cells in each population of thymic iNKT cells. Data are pooled from three independent experiments with 2--3 mice in each. ^\*\*\*\*^*p*\<0.0001 (one-way ANOVA, Tukey's multiple comparisons test) Each symbol represents an individual mouse; small horizontal lines indicate the mean. (**E**) Expression of *Tbx21*^GFP^, ROR-γt and human CD2 in CCR7^+^ iNKT cells sorted from BALB/c *Tbx21*^GFP^ KN2 mice before intra-thymic transfer (left column) or 5 days after transfer in the thymus of congenic BALB/c recipient mice (right column). (**F**) Frequency of *Tbx21*^GFP+^, ROR-γt^+^ or human CD2^+^ cells in donor cells before or 5 days after intra-thymic transfer into the thymus of congenic BALB/c recipient mice. Each symbol represents an individual recipient mouse; small horizontal lines indicate the mean. (**G**) SPADE analysis of thymic iNKT cells from B6 KN2 mice supports that CCR7^+^ NKTp are a distinct lineage from the effector subsets, NKT1, NKT2 and NKT17. Representative figure shows differential expression of human CD2 in each population of iNKT cells. (**H**) CCR7 and PD-1 distinguish two cell populations (top row, right column) within PLZF^hi^ iNKT cells (top row, left column), and expression of human CD2 and CD44 in CCR7^+^ NKTp (grey), NKT1 (green), NKT2 (red) and NKT17 (blue) are shown as overlays (bottom row). Data are representative of 3 independent experiments with 3 mice in each. (**I**) Expression of *Rag2*^GFP^ together with CCR7 (middle column) in thymic MAIT cells (far left column), and expression of CD24 and CD69 in CCR7^+^ and CCR7^--^ MAIT cells with different level of *Rag2*^GFP^ (far right two columns). Data are representative of 2 independent experiments with 3 mice in each.\
10.7554/eLife.34793.006Figure 1---source data 1.High proliferative and precursor potential of CCR7^+^ iNKT cells.\
10.7554/eLife.34793.007Figure 1---source data 2.Thymic CCR7^+^ iNKT cells are distinguished from stage 0 iNKT cells and give rise to iNKT subsets in periphery.\
10.7554/eLife.34793.008Figure 1---source data 3.Consistent, robust and unbiased labeling of thymocytes by intra-thymic injection of biotin.](elife-34793-fig1){#fig1}

To confirm that the CCR7^+^ iNKT cells were at an early developmental stage, we sought to track a \'wave' of developing iNKT cells using busulfan induced bone marrow chimeras ([Figure 1---figure supplement 2A](#fig1s2){ref-type="fig"}). We showed that, within CD45.1^+^ donor derive CD1d tetramer^+^ iNKT cells, the immature CD24^+^ CD44^−^ stage 0 iNKT cells were enriched at an early time point (4 weeks) and contracted at a later time point (5 weeks), while the NK1.1^+^ CD44^+^ mature iNKT cells were scarce at 4 weeks but abundant at 5 weeks ([Figure 1---figure supplement 2B](#fig1s2){ref-type="fig"}), suggesting this approach tracks the developmental steps of iNKT cells. With this approach, CCR7^+^ iNKT cells (with lower CD44 and T-bet) were abundant at the early time point (4 weeks) after bone marrow introduction and decreased at the later time point (5 weeks) (with increased CD44 and T-bet) ([Figure 1---figure supplement 2C](#fig1s2){ref-type="fig"}).

As CCR7^+^ iNKT cells expressed a high level of LEF1 ([Figure 1C](#fig1){ref-type="fig"}), a transcription factor that is essential for iNKT cells proliferation, we examined Ki67 expression. Most CCR7^+^ iNKT cells expressed Ki67 (\>75%) compared to the three effector subsets or the stage 0 iNKT cells ([Figure 1D](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1B,C](#fig1s1){ref-type="fig"}), suggesting they are highly proliferative. Stage 0 iNKT cells received strong TCR signal during agonist selection which could be indicated by the level of *Nr4a1* using *Nr4a1*^GFP^ mice (also known as Nur77^GFP^ mice which will be used throughout the manuscript) ([@bib31]). Highly proliferative as CCR7^+^ iNKT cells are, the Nur77^GFP^ could be diluted were they not continuously receiving TCR stimulation. We showed CCR7^+^ iNKT cells had much lower level of Nur77^GFP^ than stage 0 iNKT cells ([Figure 1---figure supplement 2D,E](#fig1s2){ref-type="fig"}). A previous study suggested that the transcription factor Egr2 controls the development of iNKT cells and is highly expressed in iNKT thymic precursors ([@bib35]). Consistently, we observed a high expression of Egr2 in CCR7^+^ iNKT cells while most thymic iNKT cells were positive for Egr2 expression ([Figure 1C](#fig1){ref-type="fig"}). Moreover, consistent with a previous report that iNKT cells go through the CD4^+^ stage after stage 0 iNKT cells ([@bib4]), we showed CCR7^+^ iNKT cells indeed exclusively expressed CD4, but not CD8 ([Figure 1C](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}).

These data raise the possibility that CCR7^+^ iNKT cells serve as progenitors for differentiation into effector subsets. We then directly assessed the potential of CCR7^+^ iNKT cells to develop into iNKT effector subsets by sorting CCR7^+^ thymocytes (CD4^+^ *Tbx21*^GFP--^ huCD2^--^ CD24^--^ CD8^--^) from *Tbx21*^GFP^/KN2 mice and injecting them intra-thymically into congenic hosts. We used an ultrasound guided imaging technique to obtain accurate and efficient intra-thymic injection ([Figure 1---figure supplement 3A](#fig1s3){ref-type="fig"}). Five days after intra-thymic transfer, all three effector subsets, NKT1, NKT2 and NKT17 cells were detected ([Figure 1E,F](#fig1){ref-type="fig"}). To test the precursor potential of thymic CCR7^+^ iNKT cells in the periphery, we also injected the sorted CCR7^+^ thymocytes intravenously into congenic hosts and detected substantial differentiation of NKT1, NKT2 and NKT17 cells in the spleen ([Figure 1---figure supplement 2F,G](#fig1s2){ref-type="fig"}), demonstrating that iNKT progenitors do not require the thymus for effector differentiation.

To better identify markers that can distinguish the precursor cells from cytokine producing NKT2 effector cells, we performed Spanning-tree Progression Analysis of Density-normalized Events (SPADE analysis) on total thymic iNKT cells based on a range of key transcription factors, surface markers and cytokines. Importantly, CCR7^+^ iNKT cells were clearly separated from the three major effector subsets, ([Figure 1G](#fig1){ref-type="fig"}, [Figure 1---figure supplement 2H](#fig1s2){ref-type="fig"}). Within the PLZF^hi^ iNKT cells, CCR7 and PD-1 best distinguished progenitors from effectors, and only PLZF^hi^ PD-1^+^ iNKT cells produced IL-4 (human CD2^+^) in the steady state ([Figure 1H](#fig1){ref-type="fig"}).

Previous reports suggested that the two lineages of innate-like T cells---iNKT cells and mucosal associated invariant T (MAIT) cells---have similarities in aspects of their phenotype and functions, such that developmental parallels might exist between the two ([@bib21]; [@bib40]). Indeed, similar to CCR7^+^ iNKT cells ([Figure 1A](#fig1){ref-type="fig"}), CCR7^+^ MAIT cells also had high to intermediate *Rag2*^GFP^ expression while being low for CD24 and CD69 expression, suggesting they are also at an early stage of development after agonist selection ([Figure 1I](#fig1){ref-type="fig"}). Mature MAIT cells are composed of only two distinct effector subpopulations, ROR-γt^+^ and T-bet^+^ MAIT cells ([@bib21]). CCR7^+^ MAIT cells did not express T-bet or ROR-γt ([Figure 1---figure supplement 1E](#fig1s1){ref-type="fig"}). Together, these data suggest that both CCR7^+^ iNKT cells and CCR7^+^ MAIT cells are progenitor populations that give rise to their corresponding iNKT and MAIT effector cells.

CCR7^+^ iNKT cells are the predominant emigrating iNKT cells and they depend on *Klf2* for thymic emigration {#s2-2}
------------------------------------------------------------------------------------------------------------

To investigate the phenotype of iNKT cells emigrating from the thymus, we performed intra-thymic injection of a biotinylating agent (NHS-biotin) to label thymocytes ([Figure 1---figure supplement 3A](#fig1s3){ref-type="fig"}) and analyze peripheral lymphoid organs 24 hr later ([Figure 2A](#fig2){ref-type="fig"}). This technique showed robust and unbiased labeling of nearly 50% of all thymocytes ([Figure 1---figure supplement 3B,C](#fig1s3){ref-type="fig"}) and did not interfere with the specificity of CD1d tetramer staining ([Figure 1---figure supplement 3D](#fig1s3){ref-type="fig"}). Due to the low frequency of recent thymic emigrants (RTE) amongst total peripheral T lymphocytes ([@bib6]; [@bib29]), we performed magnetic enrichment of biotin^+^ cells in the spleen. These two techniques combined offers a tool to accurately detect RTEs in periphery, as biotin^+^ splenic CD4^+^ or CD8^+^ T cells are predominantly *Rag2*^GFP+^ ([Figure 2---figure supplement 1A,B](#fig2s1){ref-type="fig"}). Using this tool, recent thymic emigrant iNKT cells (called \'RTE iNKT') could be readily detected ([Figure 2A](#fig2){ref-type="fig"}), while biotin^−^ iNKT cells within the unbound fraction are largely (\>97%) 'old' iNKT cells---those cells already residing in the periphery before intra-thymic labeling ([Figure 2A](#fig2){ref-type="fig"}). As expected, the RTE iNKT cells have higher *Rag2*^GFP^ compared to biotin^−^ iNKT cells ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}). We further found that RTE iNKT cells were highly enriched for CCR7^+^ cells compared to thymic or biotin^−^ iNKT cells ([Figure 2B](#fig2){ref-type="fig"}). Moreover, within the RTE iNKT cells, the CCR7^+^ cells expressed higher *Rag2*^GFP^ than CCR7^--^ cells ([Figure 2---figure supplement 1D](#fig2s1){ref-type="fig"}). In agreement with these data, *Rag2*^GFP+^ splenic iNKT cells were predominantly CCR7^+^, while most *Rag2*^GFP--^ splenic iNKT cells did not express CCR7 ([Figure 2---figure supplement 1E](#fig2s1){ref-type="fig"}).

![CCR7^+^ iNKT cells are enriched in the emigrating iNKT population and depend on *Klf2*.\
(**A**) Experimental scheme to track recent thymic emigrants (RTE) through intra-thymic injection of NHS-biotin (left column) followed by enrichment of biotin^+^ splenic cells 24 hr after intra-thymic labeling, compared to 'old' cells (biotin^--^ cells from spleen) (right column). (**B**) Expression of CCR7 in thymic, RTE and biotin^−^ iNKT cells, the grey shade represents thymic iNKT cells, the solid black line represents RTE iNKT cells, the dashed black line represents biotin^−^ iNKT cells (top row); frequency of CCR7^+^ cells in thymic, RTE and biotin^−^ iNKT cells, the solid grey circle represents thymic iNKT cells, the open circle represents RTE iNKT cells, the open square represents biotin^−^ iNKT cells (bottom row). Data are pooled from 5 independent experiments with 3--6 mice in each. ^\*\*\*\*^*p*\<0.0001 (one-way ANOVA) Each symbol represents an individual mouse; small horizontal lines indicate the mean. (**C**) Mixed bone marrow chimeras were generated with 25:75 ratio of donor bone marrow cells using CD45.2^+^ CD45.2^+^ B6 *Klf2* cKO cells and CD45.1^+^ CD45.2^+^ B6 Wt cells, or with 50:50 ratio of donor bone marrow cells using CD45.2^+^ CD45.2^+^ B6 Wt cells and CD45.1^+^ CD45.2^+^ B6 Wt cells. Eight weeks later, chimeras received intra-thymic labeling with NHS-biotin to track RTE among CD4, CD8 and iNKT cells. Data are representative of 2 independent experiments with 4--8 mice in each. (**D**) Statistical analysis of thymic, RTE and biotin^−^ CD4 T cells, CD8 T cells and iNKT cells in 8-week-old BM chimeras reconstituted with *Klf2* cKO and Wt cells (top row) or with Wt and Wt cells (bottom row). Data are pooled form 2 independent experiments with 4--8 mice in each. Numbers indicate the ratio between the cells derived from each donor source. ^\*\*\*\*^*p*\<0.0001 (one-way ANOVA). *ns*, not significant, *p*\>0.05 (one-way ANOVA). Each symbol represents an individual mouse; small horizontal lines indicate the mean. (**E**) Expression of *Klf2*^GFP^ in CCR7^+^ iNKT, stage 0 iNKT, CCR7^--^ iNKT cells and CD8 SP cells (top row). Normalized gMFI of *Klf2*^GFP^ in CCR7^+^ iNKT, stage 0 iNKT, CCR7^--^ iNKT cells (bottom row). Data are pooled from 2 independent experiments with 2 mice in each. ^\*\*\*\*^*p*\<0.0001 (one-way ANOVA). Each symbol represents an individual mouse; small horizontal lines indicate the mean.\
10.7554/eLife.34793.012Figure 2---source data 1.RTE iNKT cells are CCR7^+^ and depends on *Klf2* for emigration.\
10.7554/eLife.34793.013Figure 2---source data 2.RTE iNKT and CCR7^+^ RTE iNKT cells are *Rag2*GFP^+^.\
10.7554/eLife.34793.014Figure 2---source data 3.High *Klf2*^GFP^ in RTE iNKT cells.](elife-34793-fig2){#fig2}

The transcription factor Kruppel-like factor 2 (*Klf2*) is crucial for the thymic egress of conventional CD4 and CD8 lymphocytes ([@bib7]). However, its role in thymic emigration of iNKT cells is currently unknown. To test whether thymic egress of iNKT cells was dependent on *Klf2*, we analyzed mixed bone-marrow chimeras with wild type and *Klf2*-deficient bone marrow. We performed intra-thymic labeling to track RTE. As expected, *Klf2*-deficient conventional CD4 and CD8 T cells were enriched in the thymus and underrepresented amongst peripheral cells ([Figure 2C,D](#fig2){ref-type="fig"}). Similarly, *Klf2*-deficient iNKT cells were also enriched in the thymus and underrepresented amongst RTE and biotin^−^ iNKT cells populations ([Figure 2C,D](#fig2){ref-type="fig"}), suggesting thymic emigration of iNKT cells is dependent on *Klf2*. As *Klf2* regulates expression of S1PR1 ([@bib7]), this is consistent with the previously reported requirement for S1PR1 in iNKT cell thymic egress ([@bib1]). Next, we sought to assess *Klf2* expression in thymic and RTE iNKT cells using *Klf2*^GFP^ reporter mice. The majority of thymic iNKT cells did not express *Klf2*, though thymic CCR7^+^ iNKT cells or RTE iNKT cells highly expressed *Klf2* comparable to mature thymic CD8 single positive (SP) thymocytes or RTE CD8 T cells, respectively ([Figure 2E](#fig2){ref-type="fig"}, [Figure 2---figure supplement 2A](#fig2s2){ref-type="fig"}). Altogether, these results suggest that CCR7^+^ iNKT cells are the predominant thymic emigrating iNKT cell, and they do so in a *Klf2* dependent manner.

RTE iNKT are functionally immature and undergo further differentiation in the periphery {#s2-3}
---------------------------------------------------------------------------------------

In further characterizing RTE iNKT cells, we observed that T-bet^+^, and ROR-γt^+^ cells were substantially underrepresented amongst RTE iNKT cells compared to total thymic iNKT cells ([Figure 3A,B](#fig3){ref-type="fig"}), suggesting that both T-bet^+^ NKT1 and ROR-γt^+^ NKT17 cells may be resident in the thymus. This is consistent with the previously reported long-term retention of thymic NK1.1^+^ iNKT cells ([@bib5]). Similarly, thymic NKT2 cells that produce high levels of IL-4 (human CD2) were also less likely to be found amongst RTE ([Figure 3B](#fig3){ref-type="fig"}). Though CCR7^+^ iNKT cells were predominant within the RTE population, a small proportion of T-bet^+^ NKT1 cells were still observed ([Figure 3A,B](#fig3){ref-type="fig"}). However, cells within this small population failed to express Qa2, while the thymic T-bet^+^ NKT1 and splenic biotin^−^ T-bet^+^ NKT1 cells both expressed high level of Qa2 ([Figure 3C,D](#fig3){ref-type="fig"}). As Qa2 has commonly been used to mark the most mature thymocytes, this suggests that RTE NKT1 cells were recently derived from progenitors, as opposed to emigrating as a mature cell. Indeed, in cells collected 72 hr after intra-thymic labeling, we observed a progressive increase in Qa2 in RTE NKT1 cells ([Figure 3C,D](#fig3){ref-type="fig"}). Furthermore, RTE T-bet^+^ NKT1 expressed significantly higher PLZF at 24 hr, while the expression was down regulated over 72 hr ([Figure 3D](#fig3){ref-type="fig"}). Taken together, these results strongly suggested that RTE T-bet^+^ NKT1 cells were not directly derived from mature thymic NKT1 cells, but more likely recently differentiated from precursors. To further support this hypothesis, we sorted CCR7^+^ thymocytes (CD4^+^ *Tbx21*^GFP--^ huCD2^--^ CD24^--^ CD8^--^) from *Tbx21*^GFP^/KN2 mice and injected them intra-thymically into congenic hosts ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). Five days later, all three effector subsets, NKT1, NKT2 and NKT17 cells were detected in the spleen ([Figure 3---figure supplement 1B,C](#fig3s1){ref-type="fig"}), indicating CCR7^+^ iNKT cells rapidly emigrate to the periphery and serve as precursors that give rise to iNKT effector subsets.

![RTE iNKT cells are immature and undergo further differentiation after reaching periphery.\
(**A**) Expression of T-bet and ROR-γt in thymic, RTE and splenic biotin^−^ iNKT cells. Number in quadrants indicates percent cells in each (throughout). Data are representative of 3 independent experiments with 2--6 mice in each. (**B**) Frequency of T-bet^+^ NKT1, ROR-γt^+^ NKT17 cells and normalized gMFI of IL-4 (human CD2) in thymic, RTE and splenic biotin^−^ iNKT cells. The solid grey circle represents thymic iNKT cell, the open circle represents RTE iNKT cells, the open square represents biotin^−^ iNKT cells. ^\*\*^*p*=0.0048, ^\*\*\*\*^*p*\<0.0001 (one-way ANOVA). Data are pooled from 3 independent experiments with 2--6 mice in each. Each symbol represents an individual mouse; small horizontal lines indicate the mean. (**C**) Expression of Qa2 in thymic, 24 hr RTE, 72 hr RTE and splenic biotin^−^ T-bet^+^ NKT1 cells. Data are representative of 3 independent experiments with 2--3 mice in each. (**D**) Normalized gMFI of Qa2 in thymic, 24 hr RTE, 72 hr RTE and biotin^−^ T-bet^+^ NKT1 cells (left column). Normalized gMFI of PLZF in thymic, 24 hr RTE, 72 hr RTE and splenic biotin^−^ T-bet^+^ NKT1 cells (right column). ^\*\*\*\*^*p*\<0.0001 (one-way ANOVA). Data are pooled from 3 independent experiments with 2--3 mice in each. Each symbol represents an individual mouse; small horizontal lines indicate the mean.\
10.7554/eLife.34793.017Figure 3---source data 1.RTE iNKT cells are immature and mature further in periphery.\
10.7554/eLife.34793.018Figure 3---source data 2.Thymic CCR7^+^ iNKT cells emigrate to periphery and differentiate into effector subsets.](elife-34793-fig3){#fig3}

*Ccr7* deficiency impairs differentiation of iNKT effector subsets and their localization to the thymic medulla {#s2-4}
---------------------------------------------------------------------------------------------------------------

As CCR7^+^ iNKT cells serve as progenitors for all three subsets of iNKT cells in the thymus, we sought to evaluate whether CCR7 itself might regulate the differentiation of thymic iNKT cells. To test this, we created mixed bone-marrow chimeras with wild type and *Ccr7*-deficient bone marrow cells, and analyzed the phenotype of thymic iNKT cells derived from both donors. As expected, the generation of double positive (DP) thymocytes was not affected by the absence of CCR7, while iNKT cells derived from the *Ccr7*-deficient donors showed substantially impaired differentiation of all three iNKT effector subsets ([Figure 4A,B](#fig4){ref-type="fig"}). Similar to CCR7^+^ iNKT cells, CCR7^+^ MAIT cells were at early stage of development ([Figure 1I](#fig1){ref-type="fig"}) and distinct from effector MAIT cells ([Figure 1---figure supplement 1E](#fig1s1){ref-type="fig"}), which suggested the possibility of a similarly important role of CCR7 in the development of MAIT cells. In mixed bone marrow chimeras with wild type and *Ccr7*-deficient bone marrow cells, MAIT cell differentiation was also severely impaired when lacking cell-intrinsic CCR7 ([Figure 4---figure supplement 1A--C](#fig4s1){ref-type="fig"}).

![*Ccr7* deficiency impairs iNKT subsets differentiation and medullary localization.\
(**A**) Mixed bone marrow chimeras were generated with 50:50 ratio of donor bone marrow cells using CD45.2^+^ CD45.2^+^ B6 *Ccr7* KO cells and CD45.1^+^ CD45.2^+^ B6 Wt cells, or with 50:50 ratio of donor bone marrow cells using CD45.2^+^ CD45.2^+^ B6 Wt cells and CD45.1^+^ CD45.2^+^ B6 Wt cells. Eight weeks later, the frequency of thymic iNKT effector subsets and thymocytes derived from different donor source were analyzed. Data are representative of 3 independent experiments with 4--10 mice in each. Numbers adjacent to outlined areas indicate percent cells in each, throughout. (**B**) Statistical analysis of thymic iNKT subsets and DP thymocytes in 8-week-old BM chimeras reconstituted with *Ccr7* KO and Wt cells or with Wt and Wt cells. Numbers indicate the ratio between the cells derived from each donor source. ^\*\*\*^*p*=0.0001 (unpaired two tailed *t* test). ^\*\*\*\*^*p*\<0.0001 (unpaired two tailed *t* test). *ns*, not significant, *p*\>0.05 (unpaired two tailed *t* test). Data are pooled from 3 independent experiments with 4--10 mice in each. Each symbol represents an individual mouse; small horizontal lines indicate the mean. (**C**) Thymic sections of *Cd1d* KO (left column) and Wt (right column) B6 mice were stained with CD1d tetramer (red) and the DNA-binding dye DAPI (grey) to visualize iNKT cells *in situ*. (**D**) Thymic sections of BM chimeras 8 weeks after reconstituted with *Ccr7* KO and Wt cells were stained for the cortical-thymic-epithelial-cell-associated proteasomal subunit β5t (blue), CD1d tetramer (red), CD45.1 (green) and the DNA-binding dye DAPI (grey) to visualize and distinguish cortex, medulla, CD45.1^−^*Ccr7* KO iNKT and CD45.1^+^ Wt iNKT cells. Yellow outline (middle column) indicates magnified area (right column); Arrows indicate CD45.1^−^*Ccr7* KO iNKT cells (red), CD45.1^+^ Wt iNKT cells (yellow). C: Cortex; M: Medulla. (**E**) Flowcytometry analysis of thymocytes (left column), histocytometry analysis of immunofluorescence image (middle column) and localization of CD45.1^− ^*Ccr7* KO iNKT cells (red dot), CD45.1^+^ Wt iNKT cells (yellow dot) as determined by histocytometry (right column). (**F**) Frequency of iNKT cells localized in thymic medulla from 8-week-old BM chimeras reconstituted with *Ccr7* KO and Wt cells (left column) or with Wt and Wt cells (right column). ^\*^*p*=0.0141, *ns*, not significant, *p*=0.1775 (unpaired two tailed *t* test). Each symbol represents an individual mouse; small horizontal lines indicate the mean.\
10.7554/eLife.34793.021Figure 4---source data 1.CCR7 plays important role in iNKT cells differentiation and localization.\
10.7554/eLife.34793.022Figure 4---source data 2.CCR7 plays important role in MAIT cells differentiation.](elife-34793-fig4){#fig4}

It was recently shown that CCR7 responds to CCL21a produced in the thymic medulla and is essential for migration of thymocytes from the cortex to medulla ([@bib23]). To directly assess whether CCR7 directs the medullary localization of thymic iNKT cells, we performed CD1d tetramer based immunofluorescence and histocytometry analysis in the mixed bone-marrow chimeras reconstituted with wild type and *Ccr7*-deficient bone marrow donors. CD1d tetramer based immunofluorescence could specifically detect the CD1d restricted iNKT cells in the thymus ([Figure 4C](#fig4){ref-type="fig"}). Moreover, *Ccr7*-deficient iNKT cells showed significantly reduced localization in the thymic medulla compared to wild type iNKT cells ([Figure 4D--F](#fig4){ref-type="fig"}). These data suggest that, CCR7 not only plays an indispensable role in differentiation of thymic iNKT effector subsets, but also directs iNKT cells to localize in thymic medulla.

Thymic iNKT effector subsets are resident and influence thymic tissue homeostasis {#s2-5}
---------------------------------------------------------------------------------

To gain insight into the potential tissue residency of thymic iNKT effector subsets, we generated parabiotic mice, which share blood circulation through surgical joining ([Figure 5A](#fig5){ref-type="fig"}). Congenically distinct CD45.1^+^ and CD45.2^+^ mice were surgically connected for 30 days. Splenic CD4 or CD8 T cells were present at 50:50 ratios in parabiotic pairs consistent with their known circulation patterns ([Figure 5B,C](#fig5){ref-type="fig"}). In contrast, \~80% of splenic iNKT cells were of host origin ([Figure 5B,C](#fig5){ref-type="fig"}), confirming that the majority of splenic iNKT cells are not circulating ([@bib38]). Remarkably, \>95% of thymic iNKT cells were of host origin ([Figure 5B,C](#fig5){ref-type="fig"}). Considering that thymic iNKT effector subsets are negative for *Rag2*^GFP^ ([Figure 1A](#fig1){ref-type="fig"}), these data suggest that iNKT cells in the thymus are largely tissue-resident.

![Thymic iNKT effector subsets are predominantly resident and may influence thymocytes maturation.\
(**A**) Experimental scheme of parabiosis surgery. (**B**) Representative flowcytometry profile of spleen and thymus from the CD45.2^+^ host of a parabiotic pair after 30 days of parabiosis surgery, the number indicates the frequency of CD45.2^+^ (host) and CD45.1^+^ (parabiotic counterpart) cells in CD8 T cells and iNKT cells. Numbers adjacent to outlined areas indicate percent cells in each throughout. Data are representative of 2 independent experiments with 3 parabiotic pairs in each. (**C**) The frequency of cells derived from the host parabiont in splenic CD4^+^ T, CD8^+^ T and iNKT cells as well as thymic iNKT cells. Data are pooled from 2 independent experiments with 3 parabiotic pairs in each. *ns*, not significant, *p*=0.8722 (one-way ANOVA). ^\*\*\*^*p*=0.0009, ^\*\*\*\*^*p*\<0.0001 (one-way ANOVA). Each symbol represents an individual mouse; small horizontal lines indicate the mean. (**D**) CCR7^+^ *Tbx21*^GFP--^ and CCR7^--^ *Tbx21*^GFP+^ thymocytes were sorted from BALB/c *Tbx21*^GFP^ mice and intra-thymically transferred to congenic BALB/c recipients (left column). After 5 days, the donor derived iNKT cells were recovered in thymus and spleen from mice received CCR7^+^ *Tbx21*^GFP--^ thymocytes or CCR7^--^ *Tbx21*^GFP+^ thymocytes (right column). Numbers adjacent to outlined areas indicate percent cells in each throughout. Data are representative of 5 independent experiments. (**E**) Cell number of donor derived iNKT cells recovered in thymus and spleen from mice that received CCR7^+^ *Tbx21*^GFP--^ thymocytes or CCR7^--^ *Tbx21*^GFP+^ thymocytes. Data are pooled from 5 independent experiments with 2 mice in each. *ns*, not significant, *p*=0.1508 (unpaired two tailed *t* test). ^\*\*^*p*=0.0079 (unpaired two tailed *t* test). Each symbol represents an individual mouse; small horizontal lines indicate the mean. (**F**). Expression of YFP in DP thymocytes (left column) or thymic NKT1 cells (NK1.1^+^ CD44^+^) (right column), the grey shade represents cells from Wt mice, the solid green line represents cells from *Ifn-γ*^YFP^ mice; Numbers adjacent to solid black line indicate percent of *Ifn-γ*^YFP+^ cells from *Ifn-γ*^YFP^ mice; Data are representative of 4 independent experiments with 3--5 mice in each. (**G**) Frequency of *Ifn-γ*^YFP+^ cells within thymic NKT1 cells. Data are pooled from 4 independent experiments with 3--5 mice in each. Each symbol represents an individual mouse; small horizontal lines indicate the mean. (**H**) Expression of Qa2 in CD4 SP or CD8 SP thymocytes from Wt or *Cd1d* KO mice. Numbers adjacent to outlined areas indicate percent cells in each throughout. Data are representative of 5 independent experiments. (**I**) Frequency of Qa2^+^ cells in CD4 SP or CD8 SP thymocytes from Wt, *Cd1d* KO and *Ifn-γR*^KO^ mice. Data are pooled from 5 independent experiments, n = 18 (Wt), n = 11 (*Cd1d* KO), n = 6 (*Ifn-γR*^KO^). ^\*^*p*=0.0426, ^\*\*^*p*=0.0023, ^\*\*\*\*^*p*\<0.0001 (one-way ANOVA). *ns*, not significant, *p*=0.2676 (CD4 SP), *p*=0.8848 (CD8 SP) (one-way ANOVA). Each symbol represents an individual mouse; small horizontal lines indicate the mean. (**J**) Expression of RankL in thymic NKT1, NKT2 and NKT17 cells (upper panel). Normalized gMFI of RANKL in thymic NKT1, NKT2 and NKT17 cells (bottom panel). Data are representative of 3 independent experiments with 2--3 mice in each. ^\*\*^*p*=0.0027 (NKT1 *vs* NKT2), ^\*^*p*=0.0391 (NKT1 *vs* NKT17) (one-way ANOVA). (**K**) Expression of Aire in TEC from Wt, *Cd1d* KO or Aire KO mice. Numbers adjacent to outlined areas indicate percent cells in each throughout. Data are representative of 4 independent experiments. (**L**) Frequency and number of Aire^+^ mTEC (left and middle column), number of total TEC (right column) from Wt and *Cd1d* KO mice. Data are representative of 4 independent experiments, n = 5 (Wt), n = 6 (*Cd1d* KO). ^\*\*\*\*^*p*\<0.0001, ^\*\*^*p*=0.0032, ns, not significant, *p*=0.5209 (unpaired two tailed *t* test). Each symbol represents an individual mouse; small horizontal lines indicate the mean.\
10.7554/eLife.34793.025Figure 5---source data 1.Thymic iNKT cells are resident and influence thymic microenvironment.\
10.7554/eLife.34793.026Figure 5---source data 2.CD69 and CD103 are dispensable for thymic retention of NKT1 and NKT17 cells.](elife-34793-fig5){#fig5}

We also directly tested the retention or emigration of sorted thymic CCR7^+^ iNKT cells (CD4^+^ *Tbx21*^GFP--^ CD24^--^ CD8^--^) or *Tbx21*^GFP+^ NKT1 (CCR7^--^ CD24^--^ CD8^--^) cells by transferring them intra-thymically into congenic hosts. In contrast to thymic CCR7^+^ iNKT cells, wherein a substantial number of transferred cells were recovered from spleen 5 days after transfer, the transferred *Tbx21*^GFP+^ NKT1 cells were rarely recovered from spleen ([Figure 5D,E](#fig5){ref-type="fig"}), strongly suggest that CCR7^+^ iNKT cells efficiently emigrate thymus while iNKT effector subsets are retained in the thymus. Together, these results show that peripheral iNKT effector subsets are not directly derived from thymic iNKT effector subsets, but rather develop from the CCR7^+^ iNKT progenitors, and indicate that thymic and peripheral pools of iNKT effector subsets do not exchange.

Consistent with their tissue residency, NKT1 and NKT17 cells highly express the classical tissue residency molecules CD69 and CD103, respectively ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). To evaluate whether CD69 and CD103 are required for the thymic retention of NKT1 and NKT17 cells, we analyzed *Cd69*^+/+^, *Cd69*^+/--^ and *Cd69*^--/--^ mice. We observed comparable number of NKT1 cells among these mice in both thymus and spleen ([Figure 5---figure supplement 1B,C](#fig5s1){ref-type="fig"}). To block CD103 interaction with E-Cadherin on epithelial cells, monoclonal antibodies (mAb) against CD103 and E-Cadherin were intra-thymically injected three times ([Figure 5---figure supplement 1D,E](#fig5s1){ref-type="fig"}). Combined with intra-thymic biotin labeling to track RTE iNKT, we did not observe loss of thymic NKT17 cells nor increase of NKT17 cells in the RTE and peripheral iNKT cells population ([Figure 5---figure supplement 1F](#fig5s1){ref-type="fig"}). These data indicate the thymic retention of iNKT effector subsets is unlikely to solely rely on either CD69 or CD103.

That iNKT effector subsets are preferentially retained in the thymus raises the question of their function there. To ask whether NKT1 cells might have effects in the thymus, we investigated if they were producing IFN-γ in the steady state using IFN-γ reporter mice. We observed that \~50% of NKT1 (NK1.1^+^ CD44^+^) cells were *Ifn-γ*^YFP^ positive ([Figure 5F,G](#fig5){ref-type="fig"}). Furthermore, Qa2 expression on mature thymocytes was recently shown to be interferon dependent ([@bib44]), and was reduced in absence of iNKT cells ([Figure 5H,I](#fig5){ref-type="fig"}), comparable to that observed in IFN-γ receptor-deficient mice ([Figure 5I](#fig5){ref-type="fig"}), showing that the IFN-γ produced by NKT1 cells is biologically active, although the functional relevance remains unclear. Lastly, iNKT cells have been shown to regulate mTEC differentiation through the production of RANKL ([@bib43]). We demonstrate here that NKT2 and NKT17 cells are the exclusive producers of RANKL among iNKT cells ([Figure 5J](#fig5){ref-type="fig"}). Consistent with a previous report ([@bib43]), the absence of iNKT cells resulted in specific reduction of Aire^+^medullary thymic epithelial cells (mTEC), while the number of total TEC was not affected ([Figure 5K,L](#fig5){ref-type="fig"}). Together these data strongly suggest iNKT cells modulate thymic homeostasis and indicate the possibility that they might further influence T cell development. Given that different inbred strains have strikingly different ratios of iNKT effector subsets in the thymus, our data imply that retention of lipid specific effector T cells in the thymus fine-tunes T cell development and tissue homeostasis.

Discussion {#s3}
==========

Previously, PLZF^hi^ iNKT cells have been defined as NKT2 cells, however, our data strongly suggested that CCR7^+^ PLZF^hi^ iNKT cells had multi-lineage potential in both the thymus and periphery. Thus, PLZF^hi^ iNKT cells comprise a mixture of progenitors and mature IL-4 producing NKT2 effector cells. Such heterogeneity was indicated in the previous RNA-Seq analysis of \'bulk PLZF^hi^ NKT2 cells\' ([@bib26]; [@bib15]). Moreover, our data demonstrate that CCR7 not only marks the precursors but also directs iNKT cells to localize to the thymic medulla, which plays a critical role in their differentiation to effector subsets. This is consistent with a previous report, which showed that *Ccr7* deficient mice harbor fewer thymic iNKT cells ([@bib10]). Considering the predominant medullary localization of all three iNKT effector subsets ([@bib25]), it would seem that medullary factors are crucial for the differentiation and/or maintenance/survival of iNKT effector subsets. Indeed, IL-15 derived from medullary thymic epithelial cells (mTEC) was implicated in the generation of T-bet^+^ NKT1 cells ([@bib43]), ([@bib11]). Whether and how medullary factors are required for differentiation of NKT2 and NKT17 cells remains to be determined.

Another type of innate-like T cells, MAIT cells, which are restricted to MR1 and recognize riboflavin metabolites, have gained interest recently. A number of studies indicated a parallel between these iNKT cells and innate-like T cells in their development and functions ([@bib21]; [@bib40]; [@bib33]). For example, both mature iNKT and MAIT cells are poised effector cells, producing large amounts of cytokines upon stimulation; both express and depend on PLZF; and both are composed of effector subsets analogous to CD4 T helper subsets. We show here that, similar to iNKT cells, CCR7 also marks a population of immature MAIT cells after the agonist selection. However, whether CCR7 directs their localization remain to be answered.

Mature iNKT effector subsets, including NKT1, NKT2 and NKT17, exist in both the thymus and peripheral tissues ([@bib25]). Since iNKT cells originate in the thymus ([@bib14]; [@bib17]), this raises the question whether the peripheral iNKT effector cells directly arise from mature thymic iNKT effector cells or not. Previous work showed that a thymic NK1.1^−^ iNKT cell emigrates ([@bib3]; [@bib32]), but the work was performed before it was appreciated that mature NKT2 and NKT17 effector cells are also NK1.1^−^. In this study, we demonstrate that all thymic iNKT effector cells are long-term residents that do not emigrate, and that peripheral iNKT effector subsets derive from CCR7^+^ iNKT cells that emigrate from the thymus. iNKT cells can participate in immunity to infection ([@bib2]), but they can also regulate tissue homeostasis in the steady state ([@bib27]; [@bib25]; [@bib28]; [@bib26]). An effect of NKT2 cells on CD8 T cell development in the steady state is well supported by previous data showing their constitutive production of IL-4 drives Eomesodermin (Eomes) expression and a memory-like functional state in CD8 T cells ([@bib24]; [@bib25]). In this report, we further show that thymic resident NKT1 cells produce IFN-γ and promote Qa2 expression in CD4 and CD8 SP thymocytes. T cells up-regulate Qa2 expression during their maturation in the thymus, and type I interferon signaling has been implicated in this process ([@bib44]). It is possible that IFN-γ might function synergistically with type I interferon to influence Qa2 expression. Lastly, we show both NKT2 and NKT17 cells express RANK ligand, and together could promote Aire expression in mTEC in supporting central tolerance.

It is worth mentioning that a small number of CCR7^+^ iNKT cells express lower amounts of PLZF, LEF1 or CD4. Indeed, the development of iNKT cells in the thymus is a dynamic process, even though the CCR7^+^ iNKT cell population is largely immature and maintains precursor potential, it seems likely some of these cells have begun to receive development signals and to differentiate, prior to having completely lost CCR7 expression. Of interest, though CCR7 is critical for optimal differentiation of all three iNKT subsets, NKT17 cells seem to be most affected by CCR7 deficiency. Since NKT1, NKT2 and NKT17 are all localized to the thymic medulla, it is unclear what might cause this effect. Possibly, the differentiation or maintenance of NKT17 cells is more dependent on as yet undefined factors in the medullary environment.

In summary, we demonstrate here that the sub-population of CCR7^+^PLZF^hi^ iNKT cells represent a pool of precursor cells for all three iNKT effector subsets in thymus and periphery. Meanwhile, CCR7 not only marks the precursors, but also directs the medullary localization and differentiation of iNKT effector subsets. The thymic and peripheral iNKT effector subsets are resident and do not exchange, therefore depend on CCR7^+^ iNKT progenitors for their establishment.

Materials and methods {#s4}
=====================

  -------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\           Designation              Source or reference   Identifiers                                 Additional information
  (species) or resource                                                                                              
  ----------------------- ------------------------ --------------------- ------------------------------------------- ------------------------
  Antibody                anti-CCR7                BD Biosciences        Cat \# 562675                               (1:50)

  Antibody                anti-CD4                 BD Biosciences        Cat \# 563331                               (1:400)

  Antibody                anti-CD8α                BD Biosciences        Cat \# 563786                               (1:400)

  Antibody                anti-CD24                BioLegend             Cat \# 101824                               (1:200)

  Antibody                anti-NK1.1               BioLegend             Cat \# 108718                               (1:100)

  Antibody                anti-CD44                TONBO Biosciences     Cat \# 80--0441 U025                        (1:200)

  Antibody                anti-human CD2           BioLegend             Cat \# 309218                               (1:20)

  Antibody                anti-TCRβ                BD Biosciences        Cat \# 563221                               (1:200)

  Antibody                anti-PD-1                BioLegend             Cat \# 135213                               (1:100)

  Antibody                anti-CD45.1              BioLegend             Cat \# 110738                               (1:200)

  Antibody                anti-CD45.2              eBioscience           Cat \# 11-0454-81                           (1:200)

  Antibody                anti-Qa2                 BioLegend             Cat \# 121710                               (1:200)

  Antibody                anti-RANKL               eBioscience           Cat \# 12-5952-82                           (1:100)

  Antibody                anti-B220                BioLegend             Cat \# 103244                               (1:200)

  Antibody                anti-CD11c               eBioscience           Cat \# 47-0114-82                           (1:200)

  Antibody                anti-CD11b               eBioscience           Cat \# 47-0112-82                           (1:200)

  Antibody                anti-F4/80               eBioscience           Cat \# 47-4801-82                           (1:200)

  Antibody                anti-CD122               BD Biosciences        Cat \# 562960                               (1:100)

  Antibody                anti-PLZF                BD Biosciences        Cat \# 563490                               (1:200)

  Antibody                anti-ROR-γt              BD Biosciences        Cat \# 562684                               (1:200)

  Antibody                anti-T-bet               BioLegend             Cat \# 644824                               (1:200)

  Antibody                anti-Egr2                eBioscience           Cat \# 17-6691-80                           (1:100)

  Antibody                anti-Aire                eBioscience           Cat \# 50-5934-82                           (1:100)

  Antibody                anti-LEF1                Cell Signaling\       Cat \# 2230S                                (1:100)
                                                   Technology                                                        

  Antibody                anti-Rabbit IgG AF488    Invitrogen            Cat \# A11034                               (1:400)

  Antibody                anti-IL-17RB             R and D Systems       Cat \# FAB10402G                            (1:20)

  Antibody                Goat-anti-R\             Abcam                 Cat \# ab34721                              (1:200)
                          Phycoerythrin (PE)                                                                         

  Antibody                Donkey-anti-\            Abcam                 Cat \# ab150130                             (1:400)
                          Goat AF555                                                                                 

  Antibody                Rabbit-anti-β5t          MBL International     Cat \# PD021                                (1:100)

  Antibody                Goat-anti-Rabbit BV480   BD biosciences        Cat \# 564879                               (1:400)

  Antibody                anti-EpCAM               BioLegend             Cat \# 118214                               (1:200)

  Other                   streptavidin-PE          BD biosciences        Cat \# 554061                               (1:400)

  Other                   streptavidin-BV421       BioLegend             Cat \# 405225                               (1:400)

  Other                   Ulex Europaeus\          VECTOR\               FL-1061                                     (1:200)
                          Agglutinin I (UEA I)     LOBORATORY                                                        

  Commercial\             Viability dye\           TONBO Biosciences     Cat \# 13--0865 T100                        (1:500)
  assay or kit            Ghost Dye Red 780                                                                          

  Commercial\             anti-biotin MACS beads   Miltenyi              Cat \# 130-105-637                          
  assay or kit                                                                                                       

  Commercial\             anti-PE microbeads       Miltenyi              Cat \# 130-048-801                          
  assay or kit                                                                                                       

  Chemical\               Bulsulfan                MP Biomedicals        Cat \# 154906                               
  compound, drug                                                                                                     

  Chemical\               Streptavidin             Jackson Immuno\       Cat \# 016-000-113                          
  compound, drug                                   Research                                                          

  Chemical\               DNase I                  Roche                 Cat \# 10104159001                          
  compound, drug                                                                                                     

  Chemical\               Liberase TH              Roche                 Cat \# 5401127001                           
  compound, drug                                                                                                     

  Chemical\               sulfo-NHS-LC biotin      ThermoFisher\         Cat \# 21335                                
  compound, drug                                   Scientific                                                        

  Software,\              SPADE                    CytoBank              <https://www.cytobank.org/>                 
  algorithm                                                                                                          

  Software,\              Prism 7                  GraphPad              <https://www.graphpad.com/>                 
  algorithm                                                                                                          

  Software,\              ImageJ                   ImageJ                <https://imagej.nih.gov/ij/>                
  algorithm                                                                                                          

  Software,\              FlowJo v10               TreeStar Flowjo       <https://www.flowjo.com/solutions/flowjo>   
  algorithm                                                                                                          
  -------------------------------------------------------------------------------------------------------------------------------------------

Mice {#s4-1}
----

B6 (C57BL/6NCr) and B6.SJL (B6-LY5.2/Cr) mice were purchased from the National Cancer Institute. BALB/c (BALB/cJ or BALB/cBYJ as indicated), congenic CD45.1^+^ BALB/cBYJ (CByJ.SJL(B6)-Ptprca/J), CD4^Cre^ B6, *Ifn-γ*^YFP^ B6 (B6.129S4-Ifng^tm3.1Lky/J^), *Ifn-γR*^KO^ B6 (B6.129S7-Ifngr1^tm1Agt/J^), *Aire*^KO^ B6 (B6.129S2-Aire^tm1.1Doi/J^), *Ccr7*^KO^ B6 (B6.129P2(C)-Ccr7^tm1Rfor/J^), *Cd1d*^−/−^ B6 (B6.129S6-Cd1d1/Cd1d2^tm1Spb/J^) and *Cd1d*^−/−^ BALB/c.J (C.129S2-Cd1tm1Gru/J) mice were obtained from the Jackson Laboratory. *Rag2*^GFP^ B6, *Klf2*^GFP^ B6, *Klf2*^fl/fl^ B6, KN2 BALB/cBYJ and B6, *Tbx21*^GFP^ Balb/cBYJ and *Tbx21*^GFP^ KN2 BALB/cBYJ have been previously described ([@bib24]; [@bib25]; [@bib29]; [@bib36]; [@bib42]). *Cd69*^−/−^ B6 (*Cd69* KO) mice were kindly provided by Dr. Linda Cauley at University of Connecticut Health Center. CD4^Cre^*Klf2*^fl/fl^ (*Klf2* cKO) mice were generated through crossbreeding at University of Minnesota. All animal work was conducted in compliance with the protocols approved by the Institutional Animal Care and Use Committee of the University of Minnesota.

Flow cytometry and antibodies {#s4-2}
-----------------------------

Single-cell suspensions were prepared from thymus and spleen. Biotinylated PBS57 loaded or unloaded CD1d monomers and MR1--5--OP--RU or control MR1--Ac--6--FP monomers were obtained from the tetramer core of the US National Institutes of Health and tetramerized with streptavidin-PE (invitrogen) or streptavidin-APC (invitrogen) at the ratio of 4:1. For staining of CCR7, cells were stained with antibody to CCR7 (4B12, BD Biosciences) at 37°C for 45 min. For intracellular staining of transcription factors, cells were stained with antibodies to surface makers, then fixed and permealized with a Foxp3 staining buffer set (eBioscience), and were incubated with antibodies to PLZF (R17-809, BD Biosciences), T-bet (4B10, Biolegend), ROR-γt (Q31-378, BD Biosciences), Egr2 (erongr2, eBioscience) or Aire (5H12, eBioscience). For staining of LEF1, fixed and permealized cells were incubated with antibody to LEF1 (C12A5, Cell Signaling Technology), followed by staining with secondary antibody to Rabbit IgG (A11034, Invitrogen). Antibody to mouse IL-17RB was from R and D Systems (752101, rat IgG1). Ulex Europaeus Agglutinin I (UEA I) was from VECTOR LOBORATORY. Viability dye Ghost Dye Red 780 was from TONBO Biosciences. The complete list of other antibodies used is as follows and were purchased from eBioscience, BD Biosciences or BioLegend, unless otherwise indicated: anti-CD4 (GK1.5 or RM4-4), CD8α (53--6.7), anti-CD24 (M1/69), anti-NK1.1 (PK136), anti-CD44 (IM7), anti-human CD2 (TS1/8 or RPA-2.10), anti-TCRβ (H57-597), anti-PD-1 (29F.1A12), anti-CD45.1 (A20), anti-CD45.2 (104), anti-Qa2 (695H1-9-9), anti-RANKL (IK22/5), anti-B220 (RA3-6B2), anti-CD11c (N418), anti-CD11b (M1/70), anti-F4/80 (BM8), anti-CD122 (TM-β1). Cells were analyzed on a BD LSR Fortessa or BD Fortessa X-20 and data were processed with FlowJo software.

Enrichment of iNKT cells or MAIT cells {#s4-3}
--------------------------------------

Single cell suspensions were prepared from thymus or spleen and incubated with PE-CD1d-PBS57 tetramer at 4°C or with PE-MR1--5--OP--RU tetramer at room temperature. Then anti-PE microbeads (Miltenyi) were used for immunomagnetic enrichment according to the manufacturer\'s instructions.

SPADE analysis of thymic iNKT cells {#s4-4}
-----------------------------------

Thymic iNKT cells were enriched from B6 KN2 or BALB/c KN2 thymus. Enriched iNKT cells were stained with antibodies to CCR7, TCR-β, IL-17RB, CD1d tetramer, CD24, T-bet, PD-1, PLZF, CD44, Dump (viability dye, B220, F4/80, CD11c), CD8, ROR-γt, human CD2, CD4. Total thymic iNKT cells (TCR-β^+^ CD1d tetramer^+^ CD24^--^) were subjected to SPADE analysis on Cytobank ([www.cytobank.org](http://www.cytobank.org)) based on expression of following surface markers, key transcription factors and IL-4 production: CCR7, IL-17RB, PD-1, CD44, CD4, T-bet, PLZF, ROR-γt, human CD2.

Intra-thymic and intravenous injection {#s4-5}
--------------------------------------

Thymocytes from BALB/c KN2, BALB/c *Tbx21*^GFP^ or BALB/c *Tbx21*^GFP^ KN2 mice were depleted of CD8^+^ and CD24^+^ cells (via immunomagnetic selection \[Miltenyi\]) to enrich thymic iNKT cells. CCR7^+^ CD4^+^ human CD2^--^, CCR7^+^ *Tbx21*^GFP--^, CCR7^+^ CD4^+^ *Tbx21*^GFP--^ human CD2^--^ cells or CCR7^--^ *Tbx21*^GFP+^ cells were sorted with a FACSAria. Ultrasound imaging guided intra-thymic injections were performed on congenic host mice (BALB/c) using a Vevo 2100 preclinical scanner (VisualSonics) with a MS550 transducer. Ultrasound guided intrathymic injection is described in detail at Bio-protocol ([@bib39]). Mice received intra-thymic transfer or intravenous injections of cells were analyzed 5 days after injections. For intra-thymic injection of biotin to track RTEs, mice were given \~10 µL of 1 mg/mL solution of sulfo-NHS-LC biotin. At 24 hr or 74 hr later, biotin^+^ RTEs in spleen were enriched by immunomagnetic selection (via anti-biotin MACS beads \[Miltenyi\]), and stained with streptavidin-PE or streptavidin-BV421, followed by blocking with free streptavidin (Jackson ImmunoResearch) before staining for surface markers and CD1d tetramer.

Bone marrow chimera {#s4-6}
-------------------

Bone marrow cells were prepared from the femurs and tibias of donor mice, and depleted of T cells with CD90.2 MACS beads. Recipient mice (CD45.1^+^ CD45.1^+^) were lethally irradiated (2 × 500 rads) and received 5 × 10^6^ T-cell-depleted bone marrow cells. Mixed donor cells consisted of 25% of *Klf2* cKO cells (CD45.2^+^ CD45.2^+^) and 75% of Wt cells (CD45.1^+^ CD45.2^+^) or 50% of *Ccr7* KO cells (CD45.2^+^ CD45.2^+^) and 50% of Wt cells (CD45.1^+^ CD45.2^+^) or 50% of Wt cells (CD45.2^+^ CD45.2^+^) and 50% of Wt cells (CD45.1^+^ CD45.2^+^). All chimeras were analyzed 7 or 8 weeks after transplantation unless otherwise indicated. For busulfan induced bone marrow chimeras, recipient mice (CD45.2^+^ CD45.2^+^) were injected intraperitoneal with 400 μg of busulfan on two consecutive days, and received 1 × 10^7^ T-cell-depleted bone marrow cells (CD45.1^+^ CD45.1^+^). Busulfan induced bone marrow chimeras were analyzed at 4 and 5 weeks after transplantation.

Parabiosis surgery {#s4-7}
------------------

Parabiosis surgeries were performed as previously described ([@bib36]). Briefly, mice were anesthetized with ketamine, and flank hair was shaved and further removed using Nair. After making lateral incisions, mice were joined with interrupted horizontal mattress sutures with 5--0 NOVAFIL. Additional sutures were placed through the olecranon and knee joints to secure the legs. Parabiotic pairs were analyzed 30 days after surgeries.

Preparation of thymic epithelial cells {#s4-8}
--------------------------------------

The procedure for preparation of thymic epithelial cells have been previously described ([@bib45]). Briefly, fresh thymus was digested with 0.05% \[w/v\] of Liberase TH (Roche) and 100 U/ml of DNase I (Roche) and mechanically disrupted. After complete digestion, flowcytometic analysis was performed, and total thymic epithelial cells were identified as CD45^--^ EpCAM^+^ cells.

Immunofluorescence {#s4-9}
------------------

The CD1d tetramer immunofluorescence has been described previously ([@bib25]). Briefly, fresh thymic lobes were incubated with PE-CD1d-PBS57 tetramer at 4°C overnight. The tissues were then washed with PBS and fixed in 4% paraformaldehyde (PFA) for 1 hr and snap frozen in OCT. Five micrometer sections were made and stained with Goat-anti-R Phycoerythrin (PE) (Abcam) followed by Donkey-anti-Goat AF555 (Abcam). The sections were incubated with Rabbit-anti-β5t (MBL International) and anti-CD45.1 AF647 (Biolegend) at 4°C overnight, followed by Goat-anti-Rabbit BV480 (BD biosciences). The sections were counterstained with DAPI covered with Prolong anti-fade mounting medium (Life Technologies). The images were obtained with a Leica DM6000B Epi-Fluorescent microscope.

Histocytometry {#s4-10}
--------------

The histocytometry analysis was described previously ([@bib25]; [@bib19]). Briefly, the region of interests (ROIs) were identified and the fluorochrome intensities of each ROI were quantified using ImageJ and data were exported into Excel, Prism and FlowJo software for the localization analysis.

Ultrasound imaging guided intra-thymic injection {#s4-11}
------------------------------------------------

The intra-thymic injection was guided by ultrasound imaging using the Vevo 2100 preclinical scanner (VisualSonics) with the MS550 transducer, which ranges from 32 to 40 MHz. Briefly, we identified the thymus in the ultrasound imaging, then adjusted and slid the needle under the transducer until it could be clearly visualized above the skin of the chest area. The needle was then inserted into the thymus gland, approaching continuously toward the thymus area while avoiding penetrating any attached blood vessels or going underneath the aorta. Once the needle tip was observed within the thymic area, a 10 µL volume was injected.

Statistical analysis {#s4-12}
--------------------

Prism software (GraphPad) was used for statistical analysis. Unpaired or paired two-tailed t-tests, and one-way ANOVA were used for data analysis and calculation of *p* values. Data sets (in Prism format) are available per request.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"CCR7 defines a precursor for iNKT cells in thymus and periphery\" for consideration by *eLife*. Your article has been reviewed Arup Chakraborty as the Senior Editor, a Reviewing Editor, and two reviewers. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

In this manuscript, the authors demonstrate that CCR7 is expressed by a subset of CD1d tet^+^ iNKT cells in the thymus that correspond to the previous stage 1 cells. The CCR7^+^ iNKT cells, when injected intrathymically, give rise to cells that express markers of all three iNKT lineages. A small amount of data is also provided for MAIT cells suggesting that precursors of these cells are also CCR7^+^. Furthermore, CCR7^+^ iNKT cells emigrate to the spleen in a KLF2-dependent manner. After intrathymic injection, CCR7^+^ cells give rise to all three effector iNKT subsets in the spleen. Because parabiosis experiments demonstrate little recirculation of peripheral iNKT effector cells, the authors suggest thymic CCR7^+^ iNKT cells migrate into peripheral organs and differentiate into tissue-resident cells therein. In the thymus, the effector iNKT cells express cytokines and impact differentiation of Aire^+^ mTEC. CCR7 promotes entry of iNKT into the medulla and is required for their intrathymic differentiation. Altogether, identification of CCR7^+^ iNKT progenitors is an important advance that will enable further dissection of the mechanisms governing intrathymic and peripheral iNKT differentiation. However, there is some additional data and changes to the manuscript that will be important to clarify the impact of these findings.

Note: There are several grammatical and typographical problems that should be checked throughout the manuscript.

Essential revisions:

1\) The highest priority for the revision is to demonstrate that CCR7^+^ precursors can really generate the three separate lineages. The model put forward is that CCR7^+^ iNKT in the thymus are progenitors that give rise to all 3 effector iNKT subsets in the thymus and emigrate to the periphery where they can also differentiate, at least to NKT1 T-bet^+^ cells, in the spleen. To support the claim that CCR7^+^ progenitors emigrate from the thymus and differentiate in the periphery, it should be shown that if you intravenously inject CCR7^+^ progenitors into a congenic recipient, they give rise to NKT2 and NKT17, as well as NKT1 (as in Figure 1---figure supplement 1F). In this case, the spleen may not be the right organ to examine since at least ROR-γt^+^ iNKT are largely absent in the spleen (Figure 3A), but perhaps these iNKT types could be found in other tissues? However, in Figure 3---figure supplement 1, the authors do see ROR-γt^+^ and IL-4^+^ (huCD2^+^) cells in the spleen. Please explain this discrepancy. It is important to have a direct demonstration that the CCR7^+^ iNKT progenitors differentiate into all 3 iNKT subsets in the periphery to support the overall conclusion of the paper.

2\) The rationale for the SPADE analysis was to identify markers that could be used to gate on iNKT precursor cells: were any markers beyond the known CD1d tet^+^ CD44^-^ NK1.1^-^ CCR7^+^ CD24^-^ identified? Figure 1H doesn\'t provide additional markers.

3\) The statistical tests are not correctly applied. For example, in Figure 1D, a t-test is used to compare multiple groups to each other. Unless this data is corrected for multiple hypothesis testing, the p values will be misleading. The same applies for many other figures in the paper where more than 1 comparison is made per experiment. ANOVA might be more appropriate for these tests. ANOVA is mentioned in the methods section but not in the legends. Also, the line in each scatter graph presumably represents the mean, but this should be stated.

4\) The result identifying CCR7^+^ MAIT cell precursors was interesting and given that the authors are able to identify these cells, it is not clear why MAIT cells were not also examined in other parts of the paper. What was the transcription factor status of the CCR7 MAIT cells (PLZF, T-bet, ROR-γt)? Was MAIT cell differentiation impaired in *Ccr7* KO mice?

10.7554/eLife.34793.030

Author response

> Essential revisions:
>
> 1\) The highest priority for the revision is to demonstrate that CCR7^+^ precursors can really generate the three separate lineages. The model put forward is that CCR7^+^ iNKT in the thymus are progenitors that give rise to all 3 effector iNKT subsets in the thymus, and emigrate to the periphery where they can also differentiate, at least to NKT1 T-bet^+^ cells in the spleen. To support the claim that CCR7^+^ progenitors emigrate from the thymus and differentiate in the periphery, it should be shown that if you intravenously inject CCR7^+^ progenitors into a congenic recipient, they give rise to NKT2 and NKT17, as well as NKT1 (as in Figure 1---figure supplement 1F). It is important to have a direct demonstration that the CCR7^+^ iNKT progenitors differentiate into all 3 iNKT subsets in the periphery to support the overall conclusion of the paper.

We agree and now provide this new data in Figure 1---figure supplement 2F and G. Upon intravenous injection of CCR7^+^ progenitors, we observed differentiation into NKT1, NKT2 and NKT17 cells in the spleen 5 days later. We failed to recover a sufficient number of transferred cells from skin draining or mesenteric LN for analysis.

> In this case, the spleen may not be the right organ to examine since at least ROR-γt^+^ iNKT are largely absent in the spleen (Figure 3A), but perhaps these iNKT types could be found in other tissues? However, in Figure 3---figure supplement 1, the authors do see ROR-γt^+^ and IL-4^+^ (huCD2^+^) cells in the spleen. Please explain this discrepancy.

There is not a big discrepancy here, although we note that the different Y-axis scales in Figure 3 and Figure 3---figure supplement 1 make them appear strikingly different. The frequency of splenic ROR-γt^+^ NKT17 cells shown in Figure 3---figure supplement 1 is 3.3 ± 2.2 whereas it is either 2.8 ± 1.4 or 1.34 ± 0.7 in Figure 3, depending on whether gated on RTE or non-RTE. The frequency and number of cells are also provided in the source data file.

> 2\) The rationale for the SPADE analysis was to identify markers that could be used to gate on iNKT precursor cells: were any markers beyond the known CD1d tet^+^ CD44^-^ NK1.1^-^ CCR7^+^ CD24^-^ identified? Figure 1H doesn\'t provide additional markers.

No, we did not identify other cell surface proteins that were different, for which antibodies are available. Antibodies to CCR7 and PD-1 best distinguish progenitors from IL-4 producing NKT2 cells within the PLZF^hi^ iNKT population. This is now noted in the text subsection "CCR7^+^ iNKT and MAIT cells are at an early stage of development and represent a precursor pool for effector subsets in the thymus".

> 3\) The statistical tests are not correctly applied. For example, in Figure 1D, a t-test is used to compare multiple groups to each other. Unless this data is corrected for multiple hypothesis testing, the p values will be misleading. The same applies for many other figures in the paper where more than 1 comparison is made per experiment. ANOVA might be more appropriate for these tests. ANOVA is mentioned in the methods section but not in the legends. Also, the line in each scatter graph presumably represents the mean, but this should be stated.

ANOVA was used in statistical analysis where multiple comparisons were involved in Figure 1D, Figure 2B, Figure 2D, Figure 3B, Figure 3D, Figure 5C, Figure 5I, Figure 5J, Figure 1---figure supplement 3C, and Figure 5---figure supplement 1C. None of the conclusions we reached in earlier version of the manuscript were changed. The small bar in scatter graphs represents the mean, which is now included in the figure legends.

*4) The result identifying CCR7^+^ MAIT cell precursors was interesting and given that the authors are able to identify these cells, it is not clear why MAIT cells were not also examined in other parts of the paper. What was the transcription factor status of the CCR7 MAIT cells (PLZF, T-bet, ROR-γt)? Was MAIT cell differentiation impaired in Ccr7 KO mice?*

We performed experiments to enrich thymic MAIT cells using MR1/5-OP-RU tetramers, and stained for surface CCR7 together with intracellular transcription factors. Consistent with a previous study (Koay et al., 2016), mature MAIT cells were composed of only two subsets, ROR-γt^+^ MAIT cells and T-bet^+^ MAIT cells. We show here that CCR7^+^ MAIT cells express neither T-bet or ROR-γt (Figure 1---figure supplement 1E). We also generated *Ccr7* KO and wild-type mixed BM chimeras to check whether MAIT cell differentiation was influenced by CCR7. Consistent with what we reported for iNKT cells, we observed a severe defect in the subset differentiation of MAIT cells (much less ROR-γt^+^ and T-bet^+^ MAIT cells) in the *Ccr7* KO cells (Figure 4---figure supplement 1).
